SEC Form 4 · accession 0001209191-18-006210
TETRAPHASE PHARMACEUTICALS INC · TTPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacques Dumas
Officer — Chief ScientificOfficer
Period of report
Jan 30, 2018
Accepted (ET)
Jan 31, 2018 · 4:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001373707
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 30, 2018 | M | 8,750 | $3.69 | A | 8,750 | D | |
| Common StockF1,F2 | Jan 30, 2018 | S | 8,750 | $6.22 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F3 | $3.69 | Jan 30, 2018 | M | 8,750 | D | — | Jan 29, 2027 | Common Stock | 8,750 | 105,000 | D |
Explanation of responses
- F1The exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2017.
- F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.14 to $6.32 per share. The reporting person undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F3Vests as to 6.25% of the shares on 4/30/2017 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/31/2021.